Home › Compare › Retatrutide vs Eloralintide
Retatrutide vs Eloralintide
Retatrutide and Eloralintide are both metabolic / weight loss peptides, which is why they get recommended interchangeably — but they are different compounds with different origins. The table below sets out the differences. We give no dosing guidance.
Side by side, in plain English — what each one is, where they overlap and where they genuinely differ.
RetatrutideMetabolic / Weight Loss
EloralintideMetabolic / Weight LossAt a glance
| Retatrutide | Eloralintide | |
|---|---|---|
| Category | Metabolic / Weight Loss | Metabolic / Weight Loss |
| Typical route | SubQ | SubQ |
| Shelf life once mixed | ~30 days | ~30 days |
| Commonly reported effects | Extreme fat loss Increased energy expenditure Metabolic reset | Appetite suppression Prolonged satiety Weight loss (gradual, over weeks) Improved glycemic control |
| Reported considerations | Severe GI distress if titrated fast Elevated heart rate | Nausea (usually mild, transient) Vomiting (rare at low doses) Injection site reaction |
The differences that actually matter
Both are classed as Metabolic / Weight Loss peptides, so they get compared constantly and are often researched for overlapping reasons.
Where they overlap: extreme fat loss.
Reported mainly for Retatrutide: increased energy expenditure, metabolic reset.
Reported mainly for Eloralintide: appetite suppression, prolonged satiety, improved glycemic control.
What Retatrutide is
Retatrutide is an investigational peptide that operates as a triple agonist, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. By activating these three distinct receptors, retatrutide is understood to influence multiple metabolic pathways, including glucose regulation, appetite control, and energy expenditure. The activation of GLP-1 and GIP receptors generally promotes glucose-dependent insulin secretion and slows gastric emptying, while glu
What Eloralintide is
Eloralintide (LY3841136) is Eli Lilly's investigational selective amylin receptor agonist, engineered to activate the AMY1 receptor with approximately 12-fold greater potency than the calcitonin receptor. Amylin is a pancreatic satiety hormone co-secreted with insulin; by mimicking its action in appetite-control pathways of the hypothalamus, eloralintide increases feelings of fullness, reduces caloric intake, and slows gastric emptying — the three central pillars of amylin-driven weight regulation.
How to compare them for yourself
Anecdotes online are noisy because nobody is measuring the same thing. The only comparison that means anything is your own: log each entry with a timestamp, keep the vial ledger honest so you know what you actually got through, pick two or three metrics before you start, and look at the trend after several weeks rather than day to day.
Peptide Wizard does that part for you — Retatrutide and Eloralintide are both in the built-in reference library with a 3D vial, and your history, vial ledger and cost per entry stay private on your device.
FAQ
What is the difference between Retatrutide and Eloralintide?
Both are classed as Metabolic / Weight Loss peptides, so they get compared constantly and are often researched for overlapping reasons.
Can you log Retatrutide and Eloralintide in the same period?
Plenty of people record more than one peptide at a time. Peptide Wizard keeps a separate vial ledger and entry history for each, so you can see exactly what overlapped and when — it does not recommend combinations or doses.
Which is better, Retatrutide or Eloralintide?
There isn't a universal answer — reported responses vary a lot between individuals, which is why your own log is more informative than anyone else's anecdote. Track one variable at a time and compare your own metrics over several weeks.
Is this medical advice?
No. This page is educational reference material only. It contains no dosing guidance. Speak to a qualified healthcare professional before making any decisions.
See all peptide comparisons →
Educational reference only. This page contains no dosing guidance and is not medical advice.